Coronavirus disease 2019 outcomes in a population-based cohort of people with HIV and a matched cohort of people without HIV during Omicron variant waves

Catharine Chambers,Curtis L. Cooper,Abigail E. Kroch,Sarah A. Buchan,Claire E. Kendall,Jeffrey C. Kwong,Rahim Moideddin,Lena Nguyen,Gordon Arbess,Anita C. Benoit,Cecilia T. Costiniuk,Muluba Habanyama,Naveed Z. Janjua,Marc-André Langlois,John McCullagh,Lawrence Mbuagbaw,Nasheed Moqueet,Devan Nambiar,Sergio Rueda,Hasina Samji,Vanessa Tran,Sharon Walmsley,Aslam Anis,Ann N. Burchell
DOI: https://doi.org/10.1097/qad.0000000000003922
IF: 4.632
2024-07-13
AIDS
Abstract:HIV-mediated immunosuppression may increase the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, impair immune responses to coronavirus disease 19 (COVID-19) vaccines, or accelerate waning of immunity following vaccination, particularly for those with low CD4 + counts or unsuppressed viral loads [1–4] . Few studies have measured severe outcomes in people with HIV since the emergence of the Omicron variant [5,6] . We estimated rates of Omicron-associated COVID-19 outcomes in a population-based cohort of people with HIV in Ontario, Canada, compared with a matched cohort of people without HIV and determined if these rates differed by COVID-19 vaccination status.
immunology,infectious diseases,virology
What problem does this paper attempt to address?